CAR-T CLINICAL
TRIALS
Not a last resort β trials are where new cancer types gain access, next-gen products are tested, and treatment is often provided at no drug cost.
analyticsAt a Glance
- check_circleHundreds of active CAR-T clinical trials are running globally in 2024β2025
- check_circleChina accounts for the largest share of active CAR-T trials, with over 600 registered
- check_circleTrial targets include CD19, BCMA, CD22, GPC3, MSLN, and novel solid tumour antigens
- check_circleCancerFax can match patients to specific trials based on diagnosis and prior treatment history
Where the Next Generation Is Being Built
CAR-T clinical trials are where new cancer types gain access to cellular therapy, where next-gen products are tested, and where some patients receive treatments years before commercial availability. This isn't a last resort β it's the front edge.
βPatients who enrol in trials today are contributing to what becomes standard of care in five years β and accessing it now.β
Active Areas of CAR-T Trial Research
Solid Tumour CAR-T
Mesothelin, HER2, GD2, IL13RΞ±2, GPC3 targets. Armoured and dual-antigen constructs designed to overcome TME barriers.
Allogeneic (Off-the-Shelf) CAR-T
Donor T-cells, pre-manufactured and stored. Would eliminate manufacturing delay and reduce cost. Multiple Phase 1-2 products.
Checkpoint Inhibitor Combinations
CAR-T + PD-1/PD-L1 blockade to prevent immune evasion in the tumour microenvironment.
Logic-Gated & Safety-Switch CAR-T
Activate only when two antigens present. Built-in kill switches for safety. Improved precision for solid tumours.
Frequently Asked Questions
About Clinical Trials
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring CAR-T Clinical Trials?
Upload your reports and our team will identify currently enrolling trials relevant to your cancer type and molecular profile.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.